Alembic Pharmaceuticals has informed that the Company has received various US Food & Drug Administration (USFDA) (Tentative or Final) Product Approvals. The summary statement giving brief of all product approvals received from 1st April, 2024 till 8th May, 2024 is enclosed for information and records. Alembic has a cumulative total of 201 ANDA approvals (173 final approvals and 28 tentative approvals) from USFDA.
The above information is a part of company’s filings submitted to BSE.